Compass Rose Asset Management LP Has $15.37 Million Position in Bausch + Lomb Corporation $BLCO

Compass Rose Asset Management LP trimmed its position in Bausch + Lomb Corporation (NYSE:BLCO) by 10.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 900,000 shares of the company’s stock after selling 100,000 shares during the quarter. Bausch + Lomb accounts for 1.3% of Compass Rose Asset Management LP’s holdings, making the stock its 12th largest holding. Compass Rose Asset Management LP’s holdings in Bausch + Lomb were worth $15,372,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in BLCO. Northwestern Mutual Wealth Management Co. increased its stake in Bausch + Lomb by 729.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock valued at $30,000 after acquiring an additional 2,042 shares during the last quarter. Jones Financial Companies Lllp increased its position in Bausch + Lomb by 55.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 9,112 shares of the company’s stock valued at $132,000 after acquiring an additional 3,246 shares during the period. Focus Partners Wealth acquired a new position in Bausch + Lomb in the 3rd quarter valued at approximately $170,000. JPMorgan Chase & Co. acquired a new position in Bausch + Lomb in the 2nd quarter valued at approximately $200,000. Finally, Mission Wealth Management LP acquired a new stake in shares of Bausch + Lomb during the third quarter worth $210,000. 11.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BLCO. Deutsche Bank Aktiengesellschaft set a $16.00 price objective on shares of Bausch + Lomb in a research report on Thursday, April 30th. Wells Fargo & Company raised their price objective on shares of Bausch + Lomb from $17.00 to $18.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. Stifel Nicolaus set a $16.00 price objective on shares of Bausch + Lomb in a research note on Thursday, February 19th. Wall Street Zen raised shares of Bausch + Lomb from a “hold” rating to a “buy” rating in a research note on Saturday, April 18th. Finally, Barclays raised their price target on shares of Bausch + Lomb from $17.00 to $20.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. Four research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $17.92.

Bausch + Lomb Stock Performance

NYSE BLCO opened at $15.38 on Friday. The company has a 50-day simple moving average of $16.03 and a 200 day simple moving average of $16.59. Bausch + Lomb Corporation has a 52-week low of $11.44 and a 52-week high of $18.92. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.99 and a current ratio of 1.53. The company has a market capitalization of $5.48 billion, a PE ratio of -24.80, a price-to-earnings-growth ratio of 0.46 and a beta of 0.58.

Bausch + Lomb (NYSE:BLCO) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.02. Bausch + Lomb had a negative net margin of 4.21% and a positive return on equity of 3.60%. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.22 billion. During the same quarter in the previous year, the firm posted ($0.07) earnings per share. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. On average, research analysts predict that Bausch + Lomb Corporation will post 0.82 EPS for the current year.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.